Navigation Links
Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Date:9/6/2013

icals, Inc. in the United States and other countries.

©2013 Avanir Pharmaceuticals, Inc. All Rights Reserved.

Forward Looking Statements
Except for the historical information contained herein, the matters set forth in this press release, including statements regarding Avanir's plans, potential opportunities, financial or other expectations, projections, goals objectives, milestones, strategies, market growth, timelines, legal matters, product pipeline, clinical studies, product development, the potential benefits of its commercialized products and products under development, and statements regarding the settlement of litigation with Wockhardt and the review and approval of the settlement agreement by the U.S. Department of Justice and/or the U.S. Federal Trade Commission are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially, including the risks and uncertainties associated with, the difficulty of predicting the timing and outcome of litigation; risks that resolution of patent infringement litigation through settlement could result in investigations and/or actions by third parties, including government agencies; the market demand for and acceptance of Avanir's products domestically and internationally, delay in qualifying our manufacturing facilities that produce our products or production or regulatory problems with either third party manufacturers or API suppliers upon whom we may rely for some of our products or our own manufacturing facilities, obtaining and maintaining regulatory approvals domestically, including but not limited to the U.S. Federal Trade Commission and the Department of Justice, and internationally, the validity and enforceability of issued and pending patents, and other risks detailed from
'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Actavis
2. Avanir Pharmaceuticals Announces Publication of PRISM Pseudobulbar Affect Registry Findings
3. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Sandoz
4. Avanir Pharmaceuticals Announces Diabetes Co-Promotion Agreement with Merck
5. Avanir Pharmaceuticals Reports Fiscal 2013 Third Quarter Financial and Business Results
6. Avanir Pharmaceuticals to Participate in Two Conferences in August
7. Avanir Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
8. Avanir Pharmaceuticals Announces Accelerated Development Path for AVP-786 Following Successful Pre-IND Meeting with FDA
9. Avanir Pharmaceuticals to Participate in Two Upcoming Investor Conferences
10. Avanir Pharmaceuticals Reports Fiscal 2013 Second Quarter Financial and Business Results
11. Avanir Pharmaceuticals Announces Date of Fiscal 2013 Second Quarter Financial Results and Conference Call
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
(Date:10/1/2014)... , Oct. 1, 2014 The ... available. Interested parties can learn about the ... Health is supporting the health care continuum ... . Photo- http://photos.prnewswire.com/prnh/20140930/149504-INFO ... financials and the chief executive officer,s letter ...
(Date:10/1/2014)... , Oct. 1, 2014  Dyadic International, ... with patented and proprietary technology used to develop ... bioenergy, bio-based chemicals, biopharmaceuticals, and industrial enzymes industries, ... payment from Abengoa Bioenergy for commercial scale production ... biomass into ethanol, developed under Abengoa,s license agreement ...
Breaking Medicine Technology:Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5Cardinal Health 2014 Digital Report to Shareholders Now Available 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 2Dyadic International Reports Licensing Payment For Commercial-Scale Production Of C1-Based Cellulase Enzymes 3
... May 3, 2012   Kensey Nash Corporation (Nasdaq: KNSY ... with Royal DSM (DSM) (NYSE Euronext: DSM KON), under which DSM ... Nash through a cash tender offer, followed by a merger with ... "We are very pleased to have entered into the ...
... CAESAREA, Israel, May 2, 2012 Angioslide ... announced that it has received FDA 510(K) clearance for ... Disease in below the knee (BTK) vasculature.  The new ... potential use of PROTEUS technology.   Angioslide,s ...
Cached Medicine Technology:Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 2Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 3Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 4Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 5Kensey Nash Agrees to Be Acquired by DSM for $38.50 per Share in Cash 6Angioslide Announces FDA 510(K) Clearance of PROTEUS(TM) Below The Knee Device 2
(Date:10/2/2014)... The Business Intelligence Group today announced ... Business program. The BIG Awards specialize in recognizing ... process scored by well-known and experienced leaders and ... this year epitomize what is going right with ... Business Intelligence Group. “The sheer amount of innovation ...
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... Amy Norton HealthDay Reporter ... who have trouble smelling the roses -- literally -- may face ... research suggests. In a study of over 3,000 older Americans, ... rose, orange and peppermint were more than three times as likely ... sharp sense of smell. In fact, anosmia -- the inability ...
(Date:10/1/2014)... protein beta-amyloid is strongly associated with Alzheimer,s disease; however, ... peptide is the causal agent of the onset and ... confirmation is that beta-amyloid is not harmful when found ... when it self-assembles to form the so-called amyloid fibrils ... beta-amyloid alone, but with multiple ones because each aggregate ...
(Date:10/1/2014)... Philadelphia, PA, October 1, 2014 Patients with ... treatment, have a greatly increased risk of depression. ... therapy for chronic hepatitis C virus infection causes ... Omega-3 fatty acids, more commonly known as fish ... including lowering the risk of heart disease and ...
Breaking Medicine News(10 mins):Health News:Innovation Dominant Theme among 2014 Big Awards for Business Winners and Finalists 2Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 2Health News:Could a Fading Sense of Smell Point to Earlier Death? 3Health News:Laying siege to beta-amyloid, the key protein in Alzheimer's disease 2Health News:Omega-3 fatty acids may prevent some forms of depression 2
... Online ... clip on teen self esteem as part of its ongoing campaign and mission to affect change ... ... to the number one issue affecting today’s teen girl – low self esteem. It is a ...
... ... Championships Played on SnapSports® Volleyball Surfaces for a second year in a row. ... Pheonix, AZ (PRWEB) ... this year,s Phoenix Volleyball Festival on SnapSports® BounceBack® volleyball surfaces. The tournament is one ...
... ... and Organic Meat Raised Locally, , ... Seattle, WA (PRWEB) July 2, 2010 -- Bill the Butcher Inc. ... said J’Amy Owens, chief executive officer., , ,Located at 3800 34th Ave West in ...
... Allogeneic (donor-derived) stem cell transplant (alloSCT) may be a ... (CLL), regardless of the patient,s underlying genetic abnormalities, according ... in Blood , the journal of the American ... were diagnosed in the United States in 2009 and ...
... the brains of humans and other mammals differed from the ... presumably better). This belief was based, in part, upon the ... the brain responsible for complex cognitive behaviors. A new ... Diego School of Medicine finds that a comparable region in ...
... ... newly expanded pain treatment center in in the Los Angeles area. , ... (PRWEB) July 2, 2010 -- API and the ... Arcadia, California 91007. The Los Angeles area pain management clinic supplements the existing Encino Surgical ...
Cached Medicine News:Health News:Bellaboo Releases One Girl At A Time Documentary 2Health News:Phoenix Volleyball Festival Championships Played on SnapSports Volleyball Surfaces 2Health News:In Time for July 4th Grilling, Bill the Butcher Opens 5th Butcher Shop 2Health News:Patients with treatment-resistant CLL respond positively to stem cell transplants 2Health News:Our brains are more like birds' than we thought 2Health News:Our brains are more like birds' than we thought 3Health News:Advanced Pain Institute Opens Expanded Los Angeles Area Pain Management Center 2
... VISUCAM non-mydriatic fundus camera ... simplicity of fundus imaging. ... to set the standard ... features a unique combination ...
... Afinion HbA1c test and the ... you reliable facts conveniently available ... them. Advising the patient can ... The HbA1c Test Cartridge contains ...
An aid for advancing a pacemaker lead through the subcutaneous tissue of the chest wall to the pacemaker pocket....
The ARK-730A initiates automatic measurement at the optimum measurement point. The ARK-730A maintains fogging throughout multiple measurements, saving total examination time....
Medicine Products: